sulfasalazine has been researched along with Lymphoma in 7 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine (SASP) is a novel, potent inhibitor of cellular cystine uptake mediated by the x(c)- cystine/glutamate antiporter." | 5.32 | In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. ( Gout, PW; Robertson, MC; Simms, CR, 2003) |
| "Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the x(c)- transporter." | 5.31 | Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. ( Bruchovsky, N; Buckley, AR; Gout, PW; Simms, CR, 2001) |
| "Data on lymphoma risk in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are scarce." | 1.40 | Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. ( Askling, J; Backlin, C; Baecklund, E; Eriksson, JK; Feltelius, N; Hellgren, K; Smedby, KE; Sundstrom, C, 2014) |
| "Sulfasalazine (SASP) is a novel, potent inhibitor of cellular cystine uptake mediated by the x(c)- cystine/glutamate antiporter." | 1.32 | In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. ( Gout, PW; Robertson, MC; Simms, CR, 2003) |
| "Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the x(c)- transporter." | 1.31 | Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. ( Bruchovsky, N; Buckley, AR; Gout, PW; Simms, CR, 2001) |
| "The diagnosis of Crohn's disease with extensive involvement of small intestine and colon was first made in a 12 3/4-year-old girl, now 15 1/2 years old." | 1.27 | [Crohn disease: initial experiences with cyclosporin A in an adolescent girl]. ( Dannecker, G; Malchow, H; Niessen, KH; Ranke, MB, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hellgren, K | 1 |
| Smedby, KE | 1 |
| Backlin, C | 1 |
| Sundstrom, C | 1 |
| Feltelius, N | 1 |
| Eriksson, JK | 1 |
| Baecklund, E | 1 |
| Askling, J | 1 |
| Shenoy, P | 1 |
| Misra, R | 1 |
| Jain, M | 1 |
| Agarwal, V | 1 |
| Gout, PW | 2 |
| Simms, CR | 2 |
| Robertson, MC | 1 |
| Gallais, V | 1 |
| Grange, F | 1 |
| De Bandt, M | 1 |
| Crickx, B | 1 |
| Belaïch, S | 1 |
| Buckley, AR | 1 |
| Bruchovsky, N | 1 |
| Dannecker, G | 1 |
| Malchow, H | 1 |
| Niessen, KH | 1 |
| Ranke, MB | 1 |
| Daum, F | 1 |
| Boley, SJ | 1 |
| Cohen, MI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-05-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sulfasalazine and Lymphoma
| Article | Year |
|---|---|
Inflammatory bowel disease in the adolescent patient.
Topics: Adolescent; Adrenal Cortex Hormones; Animals; Colitis, Ulcerative; Colonic Diseases; Crohn Disease; | 1973 |
6 other studies available for sulfasalazine and Lymphoma
| Article | Year |
|---|---|
Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Psoriatic; Case-Control | 2014 |
Lymphoma-like presentation in suspected rheumatoid arthritis due to sulphasalazine hypersensitivity syndrome.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Drug Eruptions; Drug Hy | 2008 |
In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine.
Topics: Animals; Cells, Cultured; Growth Inhibitors; Humans; Lymphoma; Male; Rats; Sulfasalazine; Tumor Cell | 2003 |
[Salazosulfapyridine-induced eruption. Pustular erythroderma and pseudo-lymphomatous syndrome: 2 cases].
Topics: Adult; Dermatitis, Exfoliative; Diagnosis, Differential; Drug Eruptions; Eosinophilia; Female; Human | 1994 |
Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug.
Topics: Amino Acid Transport System y+; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Age | 2001 |
[Crohn disease: initial experiences with cyclosporin A in an adolescent girl].
Topics: Adolescent; Azathioprine; Crohn Disease; Cyclosporins; Female; Humans; Lymphoma; Osteoporosis; Predn | 1985 |